reports
Immune Design to Present at Piper Jaffray 30th Annual Healthcare Confe...
Immune Design to Present at Piper Jaffray 30th Annual Healthcare Conference SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that management will present at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, November 27, 2018 at 2:30 p.m. Eastern in New York. A live webcast of the presentation will be available online from the investor relations page of the company's corporate website at . After the live webcast, an archive of the...
Immune Design to Present at Jefferies 2018 London Healthcare Conferenc...
Immune Design to Present at Jefferies 2018 London Healthcare Conference SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14, 2018 at 9:40 a.m. GMT / 4:40 a.m. ET. A live webcast of the presentation will be available online from the investor relations page of the company's corporate website at . Aft...
Immune Design Reports Third Quarter 2018 Financial Results and Provide...
Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today reported financial results and a corporate update for the third quarter ended September 30, 2018. "Given the promising data to date with G100, our intratumoral TLR4 cancer therapy, we are aggressively advancing an expanded clinical development plan for this proprietary agent,"...
Immune Design Announces Multiple G100 Presentations at the Society for...
Immune Design Announces Multiple G100 Presentations at the Society for Immunotherapy of Cancer Meeting (SITC) Annual Meeting New data further support G100’s broad potential in hematological malignancies and solid tumors SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced multiple presentations showcasing G100, its potent intratumoral TLR4 agonist, at the annual meeting for the Society for Immunotherapy of Cancer (SITC) being held in Washington D...
Immune Design to Report Third Quarter 2018 Financial Results and Provi...
Immune Design to Report Third Quarter 2018 Financial Results and Provide Corporate Update SEATTLE and SOUTH SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report third quarter 2018 financial results after the close of U.S. financial markets on Tuesday, November 6, 2018. Immune Design management will host a webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 6, 2018 to discuss the financial results and provide a corporate...
Immune Design Announces Program Updates & Portfolio Prioritization for...
Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305 G100 development to accelerate in follicular lymphoma and beyondCMB305 to be deprioritized to support focus on G100Cash runway extended into 2021Conference call at 2:00 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced program updates for its G100 intratumoral TLR4 agonist and CMB305 cancer vaccine programs in development for the treatment of...
Immune Design to Present at Upcoming September Investor Conferences
Immune Design to Present at Upcoming September Investor Conferences SEATTLE and SOUTH SAN FRANCISCO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that senior management will present at the following upcoming investor conferences: 13th Annual Wells Fargo Securities Healthcare ConferenceWednesday, September 5, 2018 at 1:50 p.m. Eastern Time in Boston. H.C. Wainwright & Co. 20th Annual Global Investment ConferenceThursday, September 6, 2018 at 10:50 a.m. Eastern Time in New York. A live web...
Immune Design Reports Second Quarter 2018 Financial Results and Provid...
Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update G100 advancing to late-stage development following FDA feedbackConference call at 1:30 pm Pacific today SEATTLE, WA and SOUTH SAN FRANCISCO, CA, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today reported financial results and a corporate update for the second quarter ended June 30, 2018. “We have had a solid year of progress so far at Immune Design, with important advancements with CMB305, and now...
Immune Design to Report Second Quarter 2018 Financial Results and Prov...
Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update SEATTLE and SOUTH SAN FRANCISCO, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report second quarter 2018 financial results after the close of U.S. financial markets on Wednesday, August 1, 2018. Immune Design management will host a webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2018 to discuss the financial results and provide a co...
Immune Design Presents Data on the Mechanism of Action of G100 via TLR...
Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma - G100 directly targets and modifies TLR4 expressing malignant B cells making them more visible to the anti-tumor immune response- SEATTLE and SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- (Nasdaq:IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced preclinical and translational data that support the mechanism of action of G100 in patients with indolent non-H...
A director bought 50,000 shares at 4.500USD and
A director at Immune Design Corp bought 50,000 shares at 4.500USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.